The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
The 27 greenfield labs across the country ensure timely and accurate reporting
The implementation, spearheaded by Deloitte Consulting, brings together domain expertise and cutting-edge technology
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
The system is powered by advanced imaging innovations such as Amber-red Color Imaging, Triple Noise Reduction, and Extended Dynamic Range Image Processing
Subscribe To Our Newsletter & Stay Updated